Sherry Korczynski Promoted at Aquestive Therapeutics
In a noteworthy move, Aquestive Therapeutics, Inc. has appointed Sherry Korczynski as Chief Commercial Officer. This strategic promotion underscores the company’s commitment to enhancing its commercial leadership, particularly within the allergy treatment sector. Prior to her new role, Sherry served as the Senior Vice President of Sales and Marketing, showcasing significant contributions to the company's growth.
Sherry's Proven Expertise in the Allergy Market
Daniel Barber, the President and Chief Executive Officer of Aquestive, praised Sherry for her remarkable track record in commercial leadership. He highlighted her extensive experience, specifically her oversight of the EpiPen brand during her tenure at Mylan. Her background positions her effectively to steer the global commercial strategy for Anaphylm, a product aimed at revolutionizing anaphylaxis treatment.
Role Insights and Expectations
Korczynski joined Aquestive in February 2024, bringing over 20 years of experience in pharmaceutical sales and marketing. Her previous roles at leading companies such as ANI Pharmaceuticals and Eli Lilly & Company have equipped her with deep insights into allergy therapeutics, making her a valuable asset in the drive to launch Anaphylm successfully.
Vision for Anaphylm Launch
Expressing her enthusiasm about the promotion, Sherry Korczynski stated, "I am honored to take on this role at such a pivotal time for Aquestive." She emphasized the potential of Anaphylm, the first device-free, orally delivered epinephrine product designed to improve treatment for anaphylaxis. This innovative solution is on the brink of redefining how patients manage severe allergic reactions.
About Anaphylm™
Anaphylm (epinephrine) Sublingual Film is a cutting-edge product candidate developed by Aquestive. This polymer matrix-based formulation resembles a postage stamp in size yet is lightweight and easy to administer. Anaphylm is designed to dissolve without the need for water or swallowing, making it user-friendly in critical situations. Its packaging is compact and durable enough to withstand weather conditions, offering a reliable option for allergy sufferers.
Company Mission and Products
Aquestive Therapeutics prioritizes the advancement of innovative therapeutics aimed at significantly enhancing patient care. The company focuses on developing orally administered products that offer alternatives to traditional invasive treatments. Currently, it has various products available globally and is committed to collaborating with other pharmaceutical companies to bring new solutions to market using its proprietary technologies, including PharmFilm®.
Looking Ahead
As Sherry Korczynski takes on her new responsibilities, there is a palpable sense of optimism within the company regarding the upcoming launch of Anaphylm. The success of this product could greatly benefit patients navigating severe allergies and set a new standard within this essential market. Korczynski’s expertise will be crucial in achieving these goals as she guides the company’s commercial strategies.
Frequently Asked Questions
What position has Sherry Korczynski been promoted to at Aquestive?
Sherry Korczynski has been promoted to Chief Commercial Officer at Aquestive Therapeutics.
What is Anaphylm?
Anaphylm is an epinephrine sublingual film that offers an innovative approach for the treatment of anaphylaxis, designed for easy administration without swallowing.
What experience does Sherry bring to her new role?
Sherry brings over two decades of experience in the pharmaceutical industry, with significant roles focusing on commercial leadership, especially in allergy therapeutics.
How does Anaphylm differ from traditional epinephrine delivery methods?
Anaphylm is a device-free, orally delivered product, making it more accessible and easier to use in emergency situations compared to traditional options.
What is the mission of Aquestive Therapeutics?
Aquestive Therapeutics aims to advance innovative medicines that enhance patients' lives through alternative delivery methods and improved access to treatment.
